ASC30

Hong Kong, September 7, 2026 Ascletis Pharma Inc. has announced that its ordinary shares have been included as eligible...

Hong Kong, China, August 30, 2026 Ascletis Pharma Inc. announced that the first participant has been dosed in its...

Taipei, August 3, 2026 GlycoNex Inc. announced that the first patient has been successfully dosed in the first-in-human Phase...

San Francisco, August 3, 2026 AusperBio Therapeutics Inc. and Ausper Biopharma Co., Ltd. announced the initiation of patient dosing...

Hong Kong – August 3, 2026 Ascletis Pharma Inc. has initiated a global Phase III clinical development program for...

HONG KONG, June 8, 2026 Ascletis Pharma Inc. presented new clinical and preclinical data from its expanding obesity pipeline...

Hong Kong | April 27, 2026 Ascletis Pharma Inc. has announced the successful completion of enrollment in its U.S....

Hong Kong, January 26, 2026 — Ascletis Pharma continued progress in the clinical development of ASC30, its investigational oral...